Adicet Bio Statistics
Total Valuation
Adicet Bio has a market cap or net worth of $64.20 million. The enterprise value is -$77.38 million.
Important Dates
The last earnings date was Thursday, March 12, 2026, after market close.
| Earnings Date | Mar 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Adicet Bio has 9.60 million shares outstanding. The number of shares has increased by 25.49% in one year.
| Current Share Class | 9.60M |
| Shares Outstanding | 9.60M |
| Shares Change (YoY) | +25.49% |
| Shares Change (QoQ) | +82.10% |
| Owned by Insiders (%) | 0.79% |
| Owned by Institutions (%) | 35.98% |
| Float | 6.85M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.47 |
| P/TBV Ratio | 0.42 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.47, with a Debt / Equity ratio of 0.09.
| Current Ratio | 7.47 |
| Quick Ratio | 7.38 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3,392.06 |
Financial Efficiency
Return on equity (ROE) is -67.55% and return on invested capital (ROIC) is -40.40%.
| Return on Equity (ROE) | -67.55% |
| Return on Assets (ROA) | -37.00% |
| Return on Invested Capital (ROIC) | -40.40% |
| Return on Capital Employed (ROCE) | -71.49% |
| Weighted Average Cost of Capital (WACC) | 10.77% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$768,441 |
| Employee Count | 102 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -45.59% in the last 52 weeks. The beta is 1.61, so Adicet Bio's price volatility has been higher than the market average.
| Beta (5Y) | 1.61 |
| 52-Week Price Change | -45.59% |
| 50-Day Moving Average | 7.51 |
| 200-Day Moving Average | 10.35 |
| Relative Strength Index (RSI) | 38.78 |
| Average Volume (20 Days) | 109,638 |
Short Selling Information
The latest short interest is 640,053, so 6.67% of the outstanding shares have been sold short.
| Short Interest | 640,053 |
| Short Previous Month | 702,375 |
| Short % of Shares Out | 6.67% |
| Short % of Float | 9.34% |
| Short Ratio (days to cover) | 3.58 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -122.11M |
| Pretax Income | -116.80M |
| Net Income | -116.80M |
| EBITDA | -115.73M |
| EBIT | -122.11M |
| Earnings Per Share (EPS) | -$16.95 |
Full Income StatementBalance Sheet
The company has $158.53 million in cash and $14.74 million in debt, with a net cash position of $143.79 million or $14.98 per share.
| Cash & Cash Equivalents | 158.53M |
| Total Debt | 14.74M |
| Net Cash | 143.79M |
| Net Cash Per Share | $14.98 |
| Equity (Book Value) | 159.21M |
| Book Value Per Share | 14.82 |
| Working Capital | 139.40M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$95.25 million and capital expenditures -$1.74 million, giving a free cash flow of -$96.98 million.
| Operating Cash Flow | -95.25M |
| Capital Expenditures | -1.74M |
| Depreciation & Amortization | 6.38M |
| Net Borrowing | -150,000 |
| Free Cash Flow | -96.98M |
| FCF Per Share | -$10.11 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Adicet Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -25.49% |
| Shareholder Yield | -25.49% |
| Earnings Yield | -175.89% |
| FCF Yield | -146.04% |
Analyst Forecast
The average price target for Adicet Bio is $48.33, which is 622.42% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $48.33 |
| Price Target Difference | 622.42% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on December 30, 2025. It was a reverse split with a ratio of 1:16.
| Last Split Date | Dec 30, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:16 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
